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Anticholinergic drugWe quantiﬁed TGF-β1 and acetylcholine (ACh) concentrations in induced sputum supernatants (ISSs) from
18 healthy controls (HC), 22 healthy smokers (HS) and 21 COPDs. ISSs from HC, HS and COPD as well as
rhTGF-β1 were also tested in neutrophil adhesion and in mAChR2, mAChR3 and ChAT expression experi-
ments in human bronchial epithelial cells (16-HBE). Finally, we evaluated the effects of Olodaterol (a novel
inhaled β2-adrenoceptor agonist) and Tiotropium Spiriva®, alone or in combination, on neutrophil adhesion
and mAChRs and ChAT expression in stimulated 16-HBE. The results showed that 1) TGF-β1 and ACh concen-
trations are increased in ISSs from COPD in comparison to HC and HS, and TGF-β1 in HS is higher than in HC;
2) ISSs from COPD and HS caused increased neutrophil adhesion to 16-HBE when compared to ISSs from HC.
The effect of ISSs from COPD was signiﬁcantly reduced by TGF-β1 depletion or by the pretreatment with Olo-
daterol or Tiotropium alone or in combination, while the effect of ISSs from HS was signiﬁcantly reduced by
the pretreatment with Olodaterol alone; 3) mAChR2, mAChR3 and ChAT expression was increased in 16-HBE
stimulated with ISSs from COPD and TGF-β1 depletion signiﬁcantly reduced this effect on mAChR3 and ChAT
expression; 4) rhTGF-β1 increased mAChR2, mAChR3 and ChAT expression in 16-HBE; 5) Olodaterol did not
affect the expression of mAChRs and ChAT in 16-HBE. Our ﬁndings support the use of β2 long-acting and an-
ticholinergic drugs to control the bronchoconstriction and TGF-β1-mediated neutrophilic inﬂammation in
COPD.
© 2012 Elsevier B.V. All rights reserved.1. Introduction
β2-Adrenoceptor (AR)-agonists are the most potent known air-
way smooth muscle relaxants and they have been targeted for de-
cades to treat asthma and COPD. β2-AR-agonists are present in
inﬂammatory cells and inhibit their activation, the release of media-
tors, and the recruitment and the survival of these cells [1]. In
human alveolar epithelial cells stimulated with TNF-α, β2-AR agonists
exert a negative regulatory control in the secretion of CXCL8/IL-8,
GMCSF and VEGF [2] and reduce neutrophilic airway inﬂammation
in patients with mild asthma [3]. The current guidelines recommend
the regular use of β2-AR-agonists and anticholinergic-bronchodilator
agents alone or as concurrent therapy in COPD to maximize bronchodi-
lation [1,4] and, although studies suggest a potential antiinﬂammatorynd Molecular Immunology “A.
Italy. Tel.: +39 0916809121;
rights reserved.role of β2-AR-agonists and anticholinergic drugs, the antiinﬂammatory
efﬁcacy of this combination is not yet widely studied.
Airway epithelial cells are central cells in the pathogenesis of
COPD and the function of the airway epithelium is further modiﬁed
by local inﬂammatory/immune signals often promoting neutrophilic
inﬂammation in COPD [5,6]. Transforming growth factor beta (TGF-
β1) is a cytokine that affects many different cell processes in COPD
lungs and in cells importantly involved in the pathogenesis of COPD
including bronchial epithelial cells, macrophages, and ﬁbroblasts iso-
lated from COPD specimens, suggesting an impact of TGF-β1 signaling
in the development and progression of this disease [7]. TGF-β1 is also
involved in a variety of inﬂammatory processes in COPD which are
mediated by T cells and neutrophils [8]. Thus, targeting TGF-β1 sig-
naling may represent a suitable therapeutic option in COPD in the
light that TGF-β1 signaling is not well controlled by the use of cortico-
steroid treatment [9].
ACh, synthesized by choline acetyltransferase (ChAT) in different
cell types (macrophages, T lymphocytes, ﬁbroblasts and epithelial
cells) [10], is also a new emerging actor of airway inﬂammation and
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ceptors (mAChRs) [11–14]. Tiotropium is able to counteract the
proinﬂammatory activity of acetylcholine (ACh) on different cell
types [13] and reduces the activity of ACh in a guinea pig model of
neutrophilic inﬂammation and remodeling in COPD. It has been also
showed that Tiotropium is able to inhibit TGF-β1-induced matrix
metalloproteinases (MMPs) production from lung ﬁbroblasts [15] as
well as that aclidinium inhibits TGF-β1 mediated human lung ﬁbro-
blast to myoﬁbroblast transition [16]. The inhibitory effect of anticho-
linergic drugs on ACh signaling and on TGF-β1 might suggest a link
between this cytokine and non cholinergic system components such
as mAChRs and ChAT in COPD.
We hypothesized that the levels of TGF-β1 are increased in in-
duced sputum from COPD patients and that this cytokine is involved
in the pathogenesis of this disease promoting neutrophil adhesion
to bronchial epithelial cells. Since the increase in TGF-β1 was shown
to persist despite the use of corticosteroid treatment in in vivo and
in vitro studies [9,17], we investigated whether the combination of
Olodaterol (a novel generation of inhaled β2-AR-agonist) with Tiotro-
pium Spiriva® (an anticholinergic bronchodilator) might have more
effectiveness in the control of airway inﬂammation associated with
TGF-β1 and non neuronal cholinergic system components such as
mAChR2, mAChR3 and ChAT in neutrophil adhesion to human bron-
chial epithelial cells.
2. Materials and methods
2.1. Patients
We recruited three groups of subjects: healthy asymptomatic non-
smoking subjects with normal lung function (HC) (n=18), symp-
tomatic smokers with normal lung function (HS) (n=22), and
COPD (n=21). COPD subjects were deﬁned and classiﬁed according
to the criteria reported by Global Initiative for Chronic Obstructive
Lung Disease (GOLD) guidelines [18] and were classiﬁed as stage
≥1. Reversibility test to bronchodilator was performed to exclude
an asthmatic component, and the increase in forced expiratory
volume in the 1st second (FEV1) after salbutamol was lower than
12% and 200 ml compared with basal values, in all COPD subjects.
All COPD patients were in stable conditions. All COPD patients who
had routine chest X-rays and computed tomographic scans that
showed obvious emphysema were excluded.
COPD former smokers (n=13), included in the group of COPD pa-
tients, had quit smoking for at least 1 yr. Patients selected for induced
sputum (IS) collection underwent an initial 2-week run-in period. All
patients were characterized with respect to gender, age, smoking his-
tory, COPD symptoms, comorbidity, and current history of treatment.
Exclusion criteria included the following: other systemic diseases,
chronic bronchitis, chronic spontaneous, sputum production, other
lung diseases, upper and lower respiratory tract infections, treatment
with glucocorticoids or anticholinergics within 3 months before the
study and treatment with long acting beta adrenergic agonists
15 days before the study.
The local Ethics Committee approved the study, and participating
subjects gave their informed consent.
2.2. Sputum induction and processing
Sputum induction and processing were performed according to
the method of the plugs as previously described [12]. Brieﬂy after
the collection of the sputum, the selected plugs were diluted with 4
volumes of phosphate-buffered saline (PBS 1×; Gibco). The resulting
suspension was vortexed for 30 s and then centrifuged at 1000 g for
20 min. The induced sputum supernatants (ISSs) were then aspirated
and frozen at −80 °C in separate aliquots for the subsequent
biochemical analyses. The cells obtained from induced sputum werethen cytocentrifuged (Cytospin 2; Shandon, Runcorn, United King-
dom) and stained with May–Grunwald–Giemsa. For differential cell
counts, the slides were read blindly by 2 independent investigators
who counted at least 400 cells per slide.
2.3. Measurements of TGF-β1 and ACh in ISSs
TGF-β1 was measured in the ISSs by ELISA (R&D Systems Europe
Ltd, Abingdon, UK) after acidiﬁcation with HCl and neutralization
with NaOH to pH 7.0–7.4 to measure biologically active TGF-β1. The
detection limit of the assay was 50 pg/ml.
ACh was measured in the ISSs by a commercial kit (Biovision,
catalog K615-100). The kit can detect choline (Ch) and total choline
(TCh) (by adding acetylcholinesterase to the reaction that converts
ACh to Ch) with a sensitivity until 50 pmol/well (1 μM/well) by plot-
ting ﬂuorescence readings (Ex/Em 535/587 nm) against the standard
curve. This sensitivity is correspondent to the concentration of 1 μM
of TCh or Ch. Absorbance was read using a Wallac 1420 Victor2 multi-
label counter (Perkin-Elmer Life Sciences, Turku, Finland). We quan-
tiﬁed TCh and free Ch in ISSs from HC (n=18), HS (n=22) and
COPD (n=21) subjects. ACh was evaluated as differences between
TCh and Ch. Results were expressed as μM (1 μM/l). Three samples
of each group (HC, HS, and COPD)were spikedwith a known concentra-
tion of ACh (1 μM) to conﬁrm that the analyzed samples did not contain
substances that would interfere with the bioassay. The recovery of ACh
in spiked ISSs was 82.3%±2.
2.4. Epithelial cell cultures
The SV40 large T antigen-transformed 16-HBE cell line (16-HBE)
was used for these studies. 16-HBE is a cell line that retains the differen-
tiated morphology and function of normal airway epithelial cells. The
cells represent a clonal diploid (2n=6) cell line isolated from human
lung previously used to study the functional properties of bronchial ep-
ithelial cells in inﬂammation and repair processes. 16-HBE cells were
cultured as adherentmonolayers in Eagle'sminimumessentialmedium
(MEM) supplemented with 10% heat-inactivated (56 °C, 30 min) fetal
bovine serum (FBS), 1% MEM (non-essential amino acids, Euroclone),
2 mM L-glutamine and gentamicin 250 μg/ml at 37 °C in a humidiﬁed
5% CO2 atmosphere. Evidences showed that 16-HBE are similar to pri-
mary normal human bronchial epithelial (NHBE) cells (Lonza, Brussels,
Belgium), and bronchial epithelial cells (BECs) from bronchial brush-
ings in regard to the response to TGF-β1 and antiinﬂammatory drugs
[19].
2.5. 16-HBE stimulation for neutrophil adhesion
16-HBE (70,000 cells/well) were plated in standard 24-well cul-
ture plates in MEM 10% FCS and grown to conﬂuence. After 24 h
with MEM 1% FCS, the medium was replaced and 16-HBE cells were
stimulated with ISSs (10% in fresh MEM 1% FCS) from HC (n=6),
HS (n=6) and COPD (n=6) subjects for 24 h. The ISS samples
were chosen by selecting the samples with the TGF-β1 and the ACh
concentrations closest to the median of each group. To determine
the contribution of TGF-β1 present in ISSs to the observed effect on
neutrophil adhesion, the ISSs were pretreated with a monoclonal
anti-TGF-β1 antibody (4 μg/ml) (R&D Systems Europe Ltd, Abingdon,
UK) for 1 h at 4 °C to neutralize sputum TGF-β1 activity before the ad-
dition to 16-HBE. The anti-TGF-β1 antibody was selected for its ability
to neutralize the biological activity of TGF-β1 as previously described
[19]. To determine the effects of β2-AR-agonist and anticholinergic
bronchodilator compounds on neutrophil adhesion to 16-HBE,
Olodaterol (1 nM) (Boehringer Ingelheim Pharma GmbH & Co. KG,
Biberach, Germany) and Tiotropium Spiriva® (0.1 μM) (Boehringer
Ingelheim Pharma GmbH & Co. KG, Biberach, Germany) were added,
alone or in combination, to 16-HBE 1 h before the stimulation with
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TGF-β1 and ACh on neutrophil adhesion to 16-HBE, the cells were
stimulated with and without rhTGF-β1 (5 ng/ml) alone or in combi-
nation with ACh (1 μM) (Sigma St. Louis, MO) for 24 h (5% CO2 at
37 °C) in the presence or absence of Olodaterol (1 nM) alone or in
combination with Tiotropium (0.1 μM).
2.6. 16-HBE stimulation for mAChR2, mAChR3 and ChAT expression
16-HBE (150,000 cells/well) were plated into six-well culture
plates until conﬂuence with MEM 10% FBS, and grown to conﬂuence
followed by an additional 24 h under FBS-free conditions (5% CO2 at
37 °C). After 24 h, the medium was replaced with fresh MEM 1% FCS
and 16-HBE cells were stimulated with ISSs (10% in fresh MEM 1%
FCS) from 8 COPD patients or with rhTGF-β1 (eight separate experi-
ments) (5 ng/ml) for 24 h (5% CO2 at 37 °C). For 16-HBE stimulation,
ISSs were concentrated 10× (Vivaspin 6 10,000 MWC0, Vivascience,
Sartorius Group Hannover, Germany) and added to the culture medi-
um. The concentration of ISSs was modiﬁed to eliminate the mole-
cules with low molecular weight such as ACh that might interfere
with the detection of mAChR expression on 16-HBE.
To determine the contribution of TGF-β1 present in ISSs to the ob-
served effects on mAChR2, mAChR3 and ChAT expression, ISSs from
8 COPDs were pretreated with a monoclonal anti-TGF-β1 antibody
(4 μg/ml) (R&D Systems Europe Ltd, Abingdon, UK) for 1 h at 4 °C to
neutralize sputum TGF-β1 activity before the addition to 16-HBE.
To determine whether the β2-AR-agonist can affect the mAChR2,
mAChR3 and ChAT expression on 16-HBE, the cells were also pre-
treated with Olodaterol (1 nM) 1 h before the addition of ISSs from
8 COPD patients for 24 h at 37 °C.
2.7. Adhesion assay
Neutrophils from normal donors were puriﬁed as previously de-
scribed [20], resuspended in PBS (2×106/ml), labeled for 45 min at
37 °C with an equal volume of the ﬂuorochromic dye SFDA at the
ﬁnal concentration of 50 μg/ml (Molecular Probes), washed and
resuspended in PBS (0.4×106/ml). Immediately before the addition
of neutrophils, the medium with ISSs was removed from the 16-
HBE cultures and the cells were washed with warm PBS. Labeled neu-
trophils were added in a ﬁnal volume of 0.5 ml (0.2×106/well). The
plates were incubated at 37 °C for 25 min to allow neutrophils to con-
tact and to adhere to the conﬂuent 16-HBE, and total ﬂuorescence
was measured using an excitation wavelength of 485 nm and moni-
toring emission at 530 nm in a Wallac 1420 Victor multilabel counter
(PerkinElmer Life and Analytical Sciences-Wallac OY, Turku, Finland).
Nonadherent cells were then removed by washing and ﬂuorescence
was measured to evaluate bound cells. Adhesion was expressed as
percentage of the ﬂuorescence ratio of bound cells on total cells. All
test points were performed in triplicate. The baseline values repre-
sent the adhesion of neutrophils to unstimulated 16-HBE. The levels
of non-speciﬁc ﬂuorescence were calculated in 16-HBE cells
(3%±5.1%) and in the neutrophils (2.3%±7%). The % of unlabelled
cells was subtracted as background in all experimental conditions.
The efﬁciency of SDFA incorporation, evaluated using the ﬂowcyto-
metry analysis, was 87%±8% in neutrophils. At the end of incubation
time (25 min) with 16-HBE the necrosis of neutrophils was calculated
(3%±1.8).
2.8. Flow cytometry of mAChR2, mAChR3, ChAT and MAC-1 expression
The expression of mAChR2, mAChR3 and ChAT in 16-HBE cells
was evaluated by ﬂow-cytometry analyses using indirect label
immunoﬂuorescence by a FACSCalibur™ ﬂow cytometer (Becton
Dickinson, Mountain View, CA, USA) as previously described [14].
The cells (4×105/ml) were permeabilized using a commercial ﬁx-perm cell and incubated in the dark for 30 min at 4 °C with the fol-
lowing primary antibodies: a rabbit polyclonal antibody directed
against the human M2 (H-170 Santa Cruz Biotechnology, Inc., Santa
Cruz CA), a rabbit polyclonal antibody directed against the human
M3 (H-210 Santa Cruz Biotechnology, Inc., Santa Cruz CA), a mouse
monoclonal antibody directed against ChAT (Chemicon International,
USA) followed by a ﬂuorescein isothiocyanate conjugated anti-rabbit
immunoglobulin G (Dako, Glostrup, Denmark) for mAChR2 and
mAChR3 and by a ﬂuorescein isothiocyanate conjugated anti-mouse
immunoglobulin G (Dako, Glostrup, Denmark) for ChAT. FITC-
conjugated rabbit and mouse IgG1 were used as isotype negative con-
trol antibodies (Dako LSAB, Glostrup, Denmark). Results were
obtained as percentage of positive cells by ﬂowcytometry. Since the
baseline values of mAChRs and ChAT expression are high, to better
represent the signiﬁcant changes, the results of the experimental con-
ditions were plotted as fold-change compared to untreated cells
which were chosen as the reference sample.
The expression of MAC-1 was evaluated using (RPE)-conjugated
mouse monoclonal antibody direct against an anti-human CD11b/
CD18 (DAKO A/S, Glostrup, Denmark). Results of ﬂowcytometry
were expressed as percentage of positive cells.2.9. Real-time quantitative RT-PCR of mAChR2, mAChR3 and
ChAT expression
We measured the levels of mAChR2, mAChR3 and ChAT mRNA by
real-time quantitative RT-PCR in the 16-HBE cells stimulated with
ISSs from six COPD patients untreated and pretreated with a
monoclonal anti-TGF-β1 antibody and in the 16-HBE cells stimulated
with TGF-β1. Brieﬂy, total cellular RNA was extracted from 16-HBE
according to the method of Chomczynski and Sacchi, using the
RNAzol kit (Biotech Italia, Rome, Italy) as previously described [21],
and was reverse-transcribed into ﬁrst-strand complementary
DNA, using Moloney-murine leukemia virus-reverse transcriptase
(M-MLV-RT) and oligo(dT)12–18 primer (Invitrogen). Quantitative
real-time PCR of transcripts was carried out on an ABI PRISM 7900
HT Sequence Detection Systems (Applied Biosystems, Foster City,
CA, USA) using speciﬁc FAM-labeled probe and primers (prevalidated
TaqMan Gene expression Assay for mAChR2 Hs00265208m1;
mAChR3 Hs00327458m1 and ChAT, Hs00253141m1; Applied Biosys-
tems). Gene expression was normalized to glyceraldehyde-3
phosphate dehydrogenase (GAPDH) endogenous control gene.
GAPDH gene expression was used as endogenous control. Gene
expression levels were expressed as threshold cycle crossover points
considered as previously described [22].2.10. Neutrophils stimulation for MAC-1 expression
Neutrophils were resuspended and cultured at the concentration
of 4×105/ml in vials with fresh RPMI 1% FCS and were stimulated
for 2 h with concentrated ISSs from HC (n=6), HS (n=6) and
COPD (n=6). At the end of the incubation time, neutrophils were
assessed as described below for macrophage-1 antigen (MAC-1)
CD11b/CD18 expression. In addition we tested the effect of Tiotro-
pium and Olodaterol, alone or in combination, on MAC-1 expression
generated to ISSs from 6 COPDs.2.11. Statistical analysis
Statistical analysis for multiple comparisons was calculated using
Kruskal–Wallis with ANOVA tests followed by Bonferroni–Dunn cor-
rection for multiple comparisons. ANOVA with Fisher test correction
was used for the analysis of the data obtained from in vitro experi-
ments. A p value b0.05 was considered as statistically signiﬁcant.
Table 1
Demographic characteristics of patients.
HC (n=18) HS
(n=22)
COPD
(n=21)
p Value
HC vs HS HC vs COPD HS vs COPD
Age, yr 66±7 65.5±3 64±13 ns ns ns
Gender, male/female 7/11 10/11 12/10 – – –
FEV1, % predicted 109.2±10.6 102±15 63.7±23.5 ns b0.0001 b0.01
FVC, % predicted 101.2±13.7 114.1±15 70.6±21.2 ns b0.02 b0.03
FEV1/FVC (%) 90.5±2 84.3±5.0 63.4±10.0 ns b0.002 b0.03
Smoking, pack/yr 0 65.7±18.3 60±24.8 b0.001 b0.001 ns
Data are presented as mean±SD. Abbreviations: HC = healthy asymptomatic nonsmoking subjects with normal lung function; HS = asymptomatic smokers with normal lung
function; COPD = subjects with Chronic Obstructive Pulmonary Disease; FEV1 = forced expiratory volume in one second; FVC = forced vital capacity. Statistical analysis for
multiple comparisons was calculated using Kruskal–Wallis and nonparametric ANOVA tests followed by Bonferroni–Dunn correction for multiple comparisons.
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3.1. Demographic characteristic of patients and differential cell counts
of ISS
The patients' characteristics are summarized in Table 1. The re-
sults of the differential cell counts of induced sputum samples
showed a signiﬁcant increase in the number of cells in HS and COPD
subjects. In HS, this increase reﬂected an increase in the number of
both macrophages and neutrophils, whereas in COPD subjects neu-
trophils showed a large increase with the number of macrophages
being signiﬁcantly lower than in HS and in HC. Eosinophils resulted
signiﬁcantly higher in COPD subjects than in HC, whereas lympho-
cytes did not show signiﬁcant differences among the three study
groups (Table 2).
3.2. Levels of TGF-β1 and ACh in ISSs
The evaluation of TGF-β1 concentrations in ISSs showed signiﬁ-
cantly increased levels in HS subjects and COPD patients when com-
pared with HC subjects, while no statistically signiﬁcant differences
were observed between HS subjects and COPD patients (Fig. 1A).
ACh concentrations were signiﬁcantly increased in ISSs from COPD
patients when compared with HS and HC subjects. No statistically sig-
niﬁcant differences were observed between HS and HC (Fig. 1B).
3.3. Effect of ISSs on neutrophil adhesion to 16-HBE cells
The stimulation of 16-HBE cells with ISSs from HC, HS and COPD
subjects promoted different degrees of adhesion between neutrophils
and 16-HBE cells. ISSs from COPD patients and from HS subjects gen-
erated higher levels of adhesion in comparison to ISSs from HC sub-
jects (Fig. 2A). Interestingly, the adhesion generated by ISSs from
COPD subjects was signiﬁcantly inhibited by the addition of an anti-
TGF-β1 antibody demonstrating that TGF-β1 is involved, at least
partly, in this phenomenon. No effects on the 16-HBE–neutrophil
adhesion were seen by the addition of the same monoclonalTable 2
Total and differential cell count from induced sputum.
HC
(n=18)
HS
(n=22)
COP
(n=
Macrophages (%) 85±9 54±7.2 24.6
Neutrophils (%) 21.3±2.0 48±5 73
Lymphocytes (%) 0.6±03 0.7±09 1.2
Eosinophils (%) 0.1±0.2 0.9±06 0.8
Epithelial cells (%) 0.7±0.8 0.5±0.9 0.4
Total cells (106/g ISS) 3.8±3.2 4.3±0.5 6.6
Data are presented as mean±SD.
Abbreviations: HC = healthy asymptomatic nonsmoking subjects with normal lung function;
Obstructive Pulmonary Disease. Statistical analysis for multiple comparisons was calculated us
tion for multiple comparisons.antibody in the cultures with ISSs from HS and HC (Fig. 2B). These
ﬁndings suggest that TGF-β1 might be responsible of the higher levels
of neutrophil adhesion and recruitment into the airways of COPD pa-
tients. The neutrophil adhesion to 16-HBE stimulated with ISSs from
HS subjects was not signiﬁcantly reduced by Tiotropium while was
inhibited by Olodaterol (Fig. 3A). Finally, the neutrophil adhesion to
16-HBE stimulated with ISSs from COPD patients was signiﬁcantly
reduced by both Olodaterol and Tiotropium alone showing an addi-
tional effect when added to the cultures in combination (Fig. 3B).
These results suggest that the neutrophil adhesion generated by
TGF-β1 might be associated with higher levels of ACh activity present
in ISSs from COPD patients than in HS where the levels of ACh are
lower than in COPD. ACh promoting the activation of mAChRs
expressed in 16-HBE regulates neutrophil adhesion via mAChRs.
Olodaterol plays an additional role in this phenomenon.3.4. Effects of ACh and rhTGF-β1 on neutrophil adhesion to 16-HBE
To further investigate the role of both ACh and TGF-β1 in this phe-
nomenon, we performed in vitro experiments aimed to mimic the air-
ways environment in COPD. ACh increased the neutrophil adhesion to
16-HBE when compared with the baseline conditions and the use of
both Tiotropium and Olodaterol alone reduced this effect. The com-
bined use of Tiotropium and Olodaterol did not further reduce neu-
trophil adhesion when compared to Tiotropium or Olodaterol alone
(Fig. 4 left panel). The stimulation of 16-HBE with TGF-β1 increased
the levels of neutrophil adhesion when compared to the baseline con-
ditions and the addition of TGF-β1 to the ACh cultured cells further
increased the levels of adhering neutrophils. The use of both Tiotro-
pium and Olodaterol alone signiﬁcantly reduced the levels of neutro-
phil adhesion to 16-HBE stimulated with TGF-β1 plus ACh and,
interestingly, the addition of the two drugs in combination further re-
duced the neutrophil adhesion to 16-HBE (Fig. 4 right panel). These
ﬁndings suggest that TGF-β1 signaling regulates the neutrophil adhe-
sion to 16-HBE promoting the mAChR expression and increasing the
response to ACh stimulation and that this phenomenon may beD
21)
p Value
HC vs HS HC vs COPD HS vs COPD
±3 b0.01 b0.002 ns
±10.2 b0.01 b0.002 ns
±0.4 ns ns ns
±0.3 ns ns ns
±0.6 ns ns ns
±7.0 ns ns ns
HS = asymptomatic smokers with normal lung function; COPD = subjects with Chronic
ing Kruskal–Wallis and nonparametric ANOVA tests followed by Bonferroni–Dunn correc-
Fig. 1. TGF-β1 and ACh concentrations in ISS samples from HC (n=18), HS (n=22) and COPD subjects (n=21). A) TGF-β1 and B) ACh levels were measured by speciﬁc commercial
available kits as described in the Materials and methods section. Data are expressed as medians and 25th to 75th percentiles (box plot) of concentrations. Error bars represent 10th and
90th. Statistical analysis was performed by Kruskal–Wallis test and Bonferroni–Dunn procedures.
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3.5. Effect of ISSs on the expression of mAChRs and ChAT in 16-HBE cells
To further clarify the role of TGF-β1 and the non neuronal cholin-
ergic system components in COPD, we investigated the role of TGF-β1
present in ISSs from COPD on mAChRs and ChAT expression. The
stimulation of 16-HBE with ISSs from COPD patients increased both
mAChRs and ChAT expression when compared to baseline. Interest-
ingly, the pre-treatment of ISSs from COPD patients with an anti-
TGF-β1 antibody signiﬁcantly reduced the COPD ISSs generated
mAChR3 and ChAT expression while no effects were exerted on the
COPD ISSs generated expression of mAChR2 (Fig. 5). These ﬁndings
suggest that the levels of TGF-β1 present in the airways of COPD pa-
tients, although do not affect mAChR2, might be responsible of the in-
duction of mAChR3 and ChAT expression in the epithelial cells during
airway inﬂammation in COPD. However other factors present in the
ISSs, apart from TGF-β1, might be involved in the increased expres-
sion of mAChR2.
The preincubation of 16-HBE with Olodaterol before the addition
of ISSs from COPD patients did not reduce the mAChRs and ChAT
expression (Fig. 6). These results suggest that the use of Olodaterol
alone is not sufﬁcient to efﬁciently counteract the TGF-β1 relatedFig. 2. Adhesion of neutrophils to 16-HBE stimulated with ISSs. A) 16-HBE were stimulated
then co-incubated with neutrophils, obtained from normal donors, for 25 min at 37 °C befo
trophils (% of ﬂuorescence). B) 16-HBE were stimulated with ISSs obtained from HC (n=6),
anti-TGF-β1 antibody for 1 h, before their addition to 16-HBE for 24 h. 16-HBE cells were th
the neutrophil adhesion assay. Results are expressed as percentage of inhibition of neutroph
Fisher test correction was used for the analysis of the data. *pb0.05 vs HC and baseline; **pproinﬂammatory activity (expression of mAChRs and ChAT in epithe-
lial cells) present in ISSs from COPD patients.3.6. Effect of rhTGF-β1 on the expression of mAChRs and ChAT in 16-HBE
The stimulation of 16-HBE with rhTGF-β1 showed increased
mAChR2, mAChR3 and ChAT protein expression in a dose dependent
manner (data not shown) with the highest levels of induced expres-
sion reached at 5 ng/ml. The preincubation of 16-HBE with Oloda-
terol (1 nM), both in the presence and absence of rhTGF-β1 (5 ng/
ml) did not affect the expression of mAChR3 and ChAT, while fur-
ther increased the expression of mAChR2 generated by rhTGF-β1
(Fig. 7).
RT-PCR analysis of mAChR2, mAChR3 and ChAT showed that the
16-HBE increased the levels of mAChR2, mAChR3 and ChAT mRNA
(as indicated by the lower number of ampliﬁcation cycles required)
after the treatment with ISSs from COPD. The levels of mAChR3 and
ChAT mRNA were reduced after the depletion of TGF-β1 from the
tested samples (Fig. 8A). However the stimulation of 16-HBE with
higher concentrations of rhTGF-β1 generated increased levels of
mAChR2, mAChR3 and ChAT mRNA (Fig. 8B) further supporting a
probable contribution of TGF-β1 on the expression of the non neuro-
nal component of cholinergic system in bronchial epithelial cells.with ISSs obtained from HC (n=6), HS (n=6) and COPD patients (n=6) for 24 h and
re the neutrophil adhesion assay. Results are expressed as percentage of adhering neu-
HS (n=6) and COPD patients (n=6) which are treated with and without a monoclonal
en incubated with neutrophils obtained from normal donors for 25 min at 37 °C before
il adhesion vs untreated ISSs. The bars represent the means±SD of values. ANOVA with
b0.01 vs HC and baseline; #pb0.001 vs HC and HS.
Fig. 3. Effect of Olodaterol and Tiotropium on neutrophil adhesion induced by ISSs from HS (n=6) subjects A) and COPD patients (n=8) B). 16-HBE stimulated with ISSs, in the
presence of Olodaterol (1 nM), alone or in combination with Tiotropium (0.1 μM), were incubated with neutrophils obtained from normal donors for 25 min at 37 °C. Results are
expressed as mean±SD of adhering neutrophils (% of ﬂuorescence). ANOVA with Fisher test correction was used for the analysis of the data. A)*pb0.001 vs HS; **pb0.001 vs HS;
B) *pb0.001 vs COPD; **pb0.0001 vs COPD.
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Since the adherence between bronchial epithelial cells and neu-
trophils may be modulated by different expression of adhesion mole-
cule on the surface of neutrophils, we next evaluated the expression
of MAC-1 on the surface of neutrophils. MAC-1 expression was in-
creased in the neutrophils stimulated with ISSs from HS and COPD
when compared to HC. The preincubation of neutrophils with Tiotro-
pium or Olodaterol alone signiﬁcantly reduced the expression of
MAC-1 in neutrophils stimulated with ISSs from COPD patients and
this expression was further reduced by the use of the two drugs in
combination (Fig. 9). These results suggest that the increased adhe-
sion generated by ISSs from COPD and related with TGFβ1 increased
expression of mAChRs and ChAT might also involve the adhesion
molecules MAC-1.
4. Discussion
This study demonstrates that, inﬂammatory components present in
the airways of COPD patients, are involved in molecular mechanismsFig. 4. Adhesion of neutrophils to 16-HBE stimulated with ACh (1 μM) alone (left panel )
expressed as adhering neutrophils (% of ﬂuorescence) vs baseline values. The bars represent
of the data. *pb0.01 vs baseline; **pb0.05 vs ACh; #pb0.03 vs ACh; ^^pb0.01 vs baseline; Xpromoting a deregulation of mAChRs expression by TGF-β1 and their
activation by ACh generating in turn neutrophils adhesion to bronchial
epithelial cells. It provides also evidences that Tiotropium (non-selective
anticholinergic drug) attenuates neutrophilic inﬂammation in COPD and
that the combinedusewithOlodaterol (novel long actingβ2AR-agonists)
may increase this effect.
Neutrophilic airway inﬂammation is associated to the pathogenesis
and to disease severity in COPD [23]. Inhaled corticosteroid therapy re-
mains somewhat controversial since it is not able to control symptoms
and neutrophilic inﬂammation. Today it is important to identify new
molecules and pathways involved in regulating and controlling neutro-
phil inﬂammation with the aim to identify new mechanisms and new
pharmacologic approaches that could better control this universal and
sometimes debilitating inﬂammatory condition in COPD. The current
therapeutic approach suggests the use of anticholinergic and β2 long-
acting drugs in the treatment of this disease. Although the use of
these drugs in combination does not inﬂuence the progression of the
disease, demonstrating that anti-cholinergic drugs and β2 long-acting
might exert also an anti-inﬂammatory effect, wemay provide some ad-
ditional information on the effects of this drug in the treatment of COPD.or with ACh (1 μM) in combination with TGF-β1 (5 ng/ml) (right panel). Results are
the means±SD of values. ANOVA with Fisher test correction was used for the analysis
pb0.05 vs TGF-β1; +pb0.001 vs TGF-β1 ACh; °°°pb0.001 vs TGF-β1 ACh.
Fig. 5. Expression of mAChR2, mAChR3 and ChAT proteins in 16-HBE stimulated with ISSs from COPD patients. A) 16-HBE were stimulated for 24 h at 37 °C with ISSs from COPD
patients (n=8) pretreated with and without an anti-TGF-β1 antibody for 1 h. B) Representative ﬂow cytometry of mAChR2 and mAChR3 and ChAT proteins of each experimental
conditions; C) representative ﬂow cytometry of FITC-conjugated rabbit and FITC-conjugated mouse (used as isotype negative control) antibodies (Dako Denmark A/S). Results were
obtained as percentage of positive cells by ﬂowcytometry and were plotted as fold-change compared to untreated cells which were chosen as the reference sample. ANOVA with
Fisher test correction was used for the analysis of the data. *pb0.05 vs baseline; **pb0.01 vs ISS COPD.
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drugs has relatively recently been included in the current guidelines at
least in certain stages of the disease. Moreover, inﬂammation is consid-
ered to be of primary pathogenic importance in COPD but the evidence
on which current understanding is based does not distinguish betweenFig. 6. Expression of mAChR2, mAChR3 and ChAT proteins in 16-HBE stimulated with ISSs fr
(1 nM) for 1 h and then with ISSs from 8 COPD patients for 24 h at 37 °C. The protein anal
mAChR3 and ChAT proteins of each experimental condition; C) representative ﬂow cytome
trol) antibodies (Dako Denmark A/S). Results were obtained as percentage of positive cells
were chosen as the reference sample. ANOVA with Fisher test correction was used for the acause and effect, and no single mechanism can account for the complex
pathology. In this scenario, the control of inﬂammationmay play an im-
portant role. Accordingly, it has been shown that anticholinergic drugs
may control the activity of ACh in a guinea pig model of neutrophilic in-
ﬂammation and remodeling of COPD [24] bothmechanisms involved inom COPD patients. A) 16-HBE were stimulated in the presence or absence of Olodaterol
ysis was performed by ﬂow cytometry; B) representative ﬂow cytometry of mAChR2,
try of FITC-conjugated rabbit and FITC-conjugate mouse (used as isotype negative con-
by ﬂowcytometry and were plotted as fold-change compared to untreated cells which
nalysis of the data. *pb0.01 vs baseline.
Fig. 7. Expression of mAChR2, mAChR3 and ChAT proteins in 16-HBE stimulated with TGF-β1. A) 16-HBE were stimulated in the presence or absence of Olodaterol (1 nM) for 24 h at 37 °C
with TGF-β1 (5 ng/ml). The protein analysis was performed by ﬂow cytometry. The bars represent mean±SD of the % of positive ﬂuorescent cells of eight separate experiments; B) repre-
sentativeﬂow cytometry ofmAChR2,mAChR3 and ChAT proteins of each experimental condition. Resultswere obtained as percentage of positive cells by ﬂowcytometry andwere plotted as
fold-change compared to untreated cells which were chosen as the reference sample. ANOVAwith Fisher test correction was used for the analysis of the data. *pb0.05 vs baseline; **pb0.01
vs baseline.
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tion in the progression of the disease and actually without a practical
use, our ﬁndings provide new information on the mechanism by
which anticholinergic drugs, alone or in combination with β2 long-
acting, might control neutrophilic inﬂammation in COPD.
Neutrophils take part in speciﬁc and highly regulated mechanisms
for controlling the expression of adhesion molecules that allow their
tethering and migration into airway sites by epithelial cell signals
generated in turn by inﬂammatory mediators [25]. Based on the ob-
servations that β2AR-agonists can have an anti-inﬂammatory activity
in primary lung epithelial cells that is independent of glucocorticoidFig. 8. Real-time quantitative RT-PCR of mAChR2, mAChR3 and ChAT was performed in A) 1
ISSs from six COPD patients treated with and without antiTGF-β1. Gene expression levels ar
number of cycles required to reach the CT, the lower the abundance of target mRNA in the
*pb0.01 vs baseline.receptors [26] and they can reduce neutrophilic airway inﬂammation
in patients with mild asthma [3], we tested and identiﬁed the antiin-
ﬂammatory effect of Olodaterol on neutrophil adhesion to bronchial
epithelial cells in an in vitro model of neutrophilic airway inﬂamma-
tion using ISSs from COPD patients and the human bronchial epithe-
lial cell line 16-HBE. Our ﬁndings show that Tiotropium and
Olodaterol, well control the neutrophil adhesion to epithelial cells in
COPD and that their use in combination has an additional effect.
We identify here increased levels of TGF-β1 and ACh in the induced
sputum of COPD patients rather than in the airways of HC and HS con-
ﬁrming that these two pathways are importantly involved in COPD6-HBE stimulated with and without hr TGF-β1 (2 ng/ml) and in B) 16-HBE treated with
e expressed as CT (crossover cycle at the threshold of PCR ampliﬁcation; the higher the
reaction). The results for panel A and B represent the means±SD of six experiments.
Fig. 9. Expression of MAC-1 in neutrophils stimulated with ISSs. A) Neutrophils were stimulated for 2 h at 37 °C with ISSs from HC (n=6), HS (n=6) and COPD patients (n=6) ISSs
from COPD patients (n=6); B) Neutrophils stimulated with ISSs from COPD (n=6) patients in the presence of Olodaterol (1 nM), alone or in combination with Tiotropium
(0.1 μM) for 2 h at 37 °C. The expression of MAC-1 was evaluated using (RPE)-conjugated mouse monoclonal antibody direct against an anti-human CD11b/CD18 (Dako Denmark
A/S). Results are expressed as mean±SD of % ﬂuorescent positive cells. ANOVA with Fisher test correction was used for the analysis of the data. *pb0.01 vs neutrophils; **pb0.001
vs neutrophils; #pb0.01 vs COPD, ##pb0.001 vs COPD.
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they may exert a pro-inﬂammatory activity. Moreover, the evidences
that the amount of ACh present in ISSs from HS has a trend toward
higher levels, not statistically signiﬁcant when compared with HC and
statistically different from COPD patients, suggest that the immune in-
ﬂammatory mechanisms originated by cigarette smoke and involved
in the production of ACh aremaintained and ampliﬁed during the cellu-
lar and molecular mechanisms of COPD [27]. Emerging evidences have
shown increased expression of TGF-β1 in COPD lungs and in primary
cells, such as epithelial cells, macrophages, cells of the immune system
or ﬁbroblasts isolated from COPD specimens, suggesting an impact of
TGF-β1 signaling on the development and progression of neutrophilic
inﬂammation in COPD. Moreover, TGF-β1 signaling regulates degranu-
lation and oxidant release by adherent human neutrophils underlining
its contribution to neutrophilic inﬂammation [28]. According to these
ﬁndings, we demonstrate here that ISSs from COPD and from HS, are
able to induce neutrophil adherence to bronchial epithelial cells in a sig-
niﬁcantly higher manner than HC and that this phenomenon is driven,
at list partly, by the presence of TGF-β1 supporting the important role
of this molecule in the neutrophilic inﬂammation in COPD. Increased
levels of TGF-β1 persist despite oral corticosteroid treatment in asthma
[29] and the in vitro TGF-β1 induced epithelial–mesenchymal transition
(EMT) in human bronchial epithelial cells is enhanced by IL-1β and not
abrogated by corticosteroids [9]. Thus, new targeted interventions may
represent a suitable therapeutic approach in COPD to control activity
and production of TGF-β1 signaling [7]. Our ﬁndings show that the
use of Tiotropium and Olodaterol is able to strongly and signiﬁcantly in-
hibit the COPD ISSs mediated neutrophil–epithelial cell adhesion
strongly supporting the concept that these two drugs, other than
being strong bronchodilators, are also important anti-inﬂammatory
drugs. The ﬁndings that they exert an additional effect in the down-
regulation of the COPD ISSs mediated neutrophil–epithelial cell adhe-
sion further support the new rising concept of their anti-inﬂammatory
activity. These results are strongly supported by the fact that ACh is con-
sidered an emerging marker of COPD. The ACh-mediated mAChR acti-
vation involves the release of chemotactic mediators for eosinophils
and neutrophils from bronchial epithelial cells and alveolar macro-
phages [11,12,30,31]. ACh is synthesized by choline acetyltransferase
(ChAT) in different cell types (macrophages, T-lymphocytes, ﬁbroblasts,
and epithelial cells) [10] and often increased levels of ChAT expression
are associated with increased production and activity of ACh [32]. The
proinﬂammatory activity of ACh can be counteracted by the use of anti-
cholinergic drugs such as Tiotropium [13]; in addition recent evidences
identiﬁed a direct relationship between Tiotropium bromide and TGF-β1 showing that, interfering with Smad and MAPK pathways in vitro,
Tiotropium is able to inhibit TGF-β1 induced MMP production from
lung ﬁbroblasts [15].
The depletion of TGF-β1 reduced the neutrophil adhesion to 16-
HBE in the cells stimulated with ISSs from COPD rather than in HS de-
spite there is no signiﬁcant difference in the amount of TGF-β1 in the
HS and COPD and despite, in in vivo conditions, in COPD patients, in-
sensitivity to TGF-β1 has been observed. These ﬁndings suggest that
high levels of TGF-β1 together with higher levels of ACh present in
ISSs from COPD are additively involved in the regulation of neutrophil
adhesion to bronchial epithelial cells since TGF-β1 promotes the ex-
pression of muscarinic receptors and ACh promotes their activation
in bronchial epithelial cells. The inhibition of neutrophil adhesion
exerted by Tiotropium in the presence of TGF-β1 might support
these explanations. It is also interesting to note that the % of inhibition
of neutrophil adhesion obtained by TGF-β1 antibody is evident in
COPD and not in HS. This lack of effect might be due to the lower levels
of ACh present in the airways of HS since, despite the increased ex-
pression of mAChR due to the TGF-β1, they are unable to be activated
by the low levels of ACh. These concepts are further supported by the
uncomplete effects of Tiotropium on the neutrophil adhesion generat-
ed with HS ISSs also in the presence of Olodaterol. Moreover, the ﬁnd-
ing that the use of Olodaterol well controls the adhesion of neutrophils
generated by ISSs from both HS and COPD, suggests the involvement
of other factors in this phenomenon independently from mAChRs.
We decided to use neutrophils from normal donors rather than
neutrophils recovered from the same subjects in order to by-pass
the bias due to the potential different expression of adhesion mole-
cules as well as to the effects of different activating factors in neutro-
phils recovered from peripheral blood of HC, HS and COPD subjects.
We were thus able to focus only on the effects on the neutrophil ad-
hesion of the mediators present in the sputum from each group of
subjects. Therefore the 16-HBE, activated with ISSs from HC, HS and
COPD, during the incubation with neutrophils for the adhesion
assay, differentially modify the adhesion of neutrophils from normal
donors due to the increased expression of adhesion molecules gener-
ated from epithelial–neutrophil interactions in the airways of COPD pa-
tients as previously described [25]. These observations support the
translation of our in vitro model to an in vivo situation of airway in-
ﬂammation in COPD. Particularly we show that ISSs from COPD pa-
tients increase the expression of MAC-1 on the neutrophils from
normal donors. This effect was controlled in vitro by the use of Oloda-
terol and Tiotropium supporting the concept that the β2 agonist
together with anticholinergic drug may be involved in the inhibition
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study is necessary to better examine the cellular andmolecular mech-
anisms of neutrophil adhesion and their inhibition by anticholinergic
drugs or by β-2 agonists [33,34].
TGF-β1 present in the ISSs from COPD patients might be involved
in the induction of mAChR3 and ChAT expression in epithelial cells
from these patients promoting an increased production and activity
of ACh in these cells during airway inﬂammation in COPD. Our ﬁnd-
ings that 16-HBE stimulated with ISSs from COPD patients display
an upregulation of the expression of mAChR3 and ChAT not con-
trolled by Olodaterol but signiﬁcantly reduced by the depletion of
TGF-β1 strongly support this hypothesis and the concept of the direct
contribution of TGF-β1 in the induction of non cholinergic system
components in epithelial cells. These observations are further sup-
ported by the induction of mAChRs and ChAT expression by higher
levels of rhTGF-β1 in 16-HBE and by the fact that this phenomenon
is not controlled by Olodaterol.
Smooth muscle bronchoconstriction is activated via mAChR3, and
mucus secretion via mAChR1 and mAChR3, while prejunctional
mAChR2 autoreceptors possess a signiﬁcant inhibitory activity, pro-
viding a negative feedback to ACh release [35]. The expression of
mAChR2 is reduced in ISS cells from COPD and increased levels
mAChR3 are present in these patients suggesting a defective inﬂam-
matory response to ACh in the airways of COPDs [12]. The increased
expression of mAChR2 might represent a defense mechanism of the
cells with the aim to downregulate the response to ACh. These cellu-
lar events can generate mechanisms of cross-talk between the activi-
ties of the different mAChRs [36] and between mAChRs and β2-
adrenoceptors [4,34,37]. The exposure to proinﬂammatory cytokines,
such as TGF-β1 and TNF-α, can modulate mAChRs [38]. Accordingly
we have shown that rhTGF-β1 and Olodaterol increase mAChR2 ex-
pression that may be the cause of a defective resolution of ACh medi-
ated response in the epithelial cells. Therefore we observed that the
use of Olodaterol alone was able to signiﬁcantly reduce the adhesion
of neutrophils generated by ISSs from COPDwith higher levels of ACh.
On the other hand, in vivo Olodaterol other than being able to potent-
ly reverse contraction induced by different stimuli in isolated human
bronchi, is able to potently reverse contraction induced by ACh chal-
lenges in anesthetized guinea pigs and dogs [39]. These observations
together with our ﬁndings support the translation in vivo of the use of
anticholinergic drugs and β-2 agonist to well control the bronchocon-
striction and inﬂammation in COPD.
In conclusion, to our knowledge, this is the ﬁrst paper demonstrating
anti-inﬂammatory effects exerted by Olodaterol. It provides also evi-
dences on additive anti-inﬂammatory effects generated by Olodaterol
and Tiotropium in combination. The combined use of β2AR-agonists
with anticholinergic drugs might be a useful alternative therapy to the
combination of β2AR-agonists and inhaled corticosteroid to control
inﬂammation in COPD. Since our in vitro studies are obtained with a
limited number of samples, further studies in a larger population of
subjects with COPD performing adequate clinical trials are required to
conﬁrm the relevant contribution of this new therapeutic approach.Funding source
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